152 related articles for article (PubMed ID: 37079976)
21. Cisplatin resistance in lung cancer is mediated by MACC1 expression through PI3K/AKT signaling pathway activation.
Zhang Q; Zhang B; Sun L; Yan Q; Zhang Y; Zhang Z; Su Y; Wang C
Acta Biochim Biophys Sin (Shanghai); 2018 Aug; 50(8):748-756. PubMed ID: 29961813
[TBL] [Abstract][Full Text] [Related]
22. Identification of upregulated exosomal miRNAs between A2780 and A2780/DDP human ovarian cancer cells by high-throughput sequencing.
Wang H; Liu L; Liu Q; Zheng J; Zheng Q; Chen Y; Xia H; Wu Q; Sun Y
J Ovarian Res; 2023 May; 16(1):94. PubMed ID: 37179363
[TBL] [Abstract][Full Text] [Related]
23. New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment.
Chen SH; Chang JY
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450627
[TBL] [Abstract][Full Text] [Related]
24. Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT.
Tan J; You Y; Xu T; Yu P; Wu D; Deng H; Zhang Y; Bie P
Toxicol Lett; 2014 Jan; 224(1):7-15. PubMed ID: 24144893
[TBL] [Abstract][Full Text] [Related]
25. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
Lee S; Choi EJ; Jin C; Kim DH
Gynecol Oncol; 2005 Apr; 97(1):26-34. PubMed ID: 15790433
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic strategies to overcome cisplatin resistance in ovarian cancer.
Song M; Cui M; Liu K
Eur J Med Chem; 2022 Mar; 232():114205. PubMed ID: 35217497
[TBL] [Abstract][Full Text] [Related]
27. cIAP2 upregulated by E6 oncoprotein via epidermal growth factor receptor/phosphatidylinositol 3-kinase/AKT pathway confers resistance to cisplatin in human papillomavirus 16/18-infected lung cancer.
Wu HH; Wu JY; Cheng YW; Chen CY; Lee MC; Goan YG; Lee H
Clin Cancer Res; 2010 Nov; 16(21):5200-10. PubMed ID: 20959404
[TBL] [Abstract][Full Text] [Related]
28. Dysregulated Signalling Pathways Driving Anticancer Drug Resistance.
Bou Antoun N; Chioni AM
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569598
[TBL] [Abstract][Full Text] [Related]
29. Dysregulation of mRNA profile in cisplatin-resistant gastric cancer cell line SGC7901.
Xie XQ; Zhao QH; Wang H; Gu KS
World J Gastroenterol; 2017 Feb; 23(7):1189-1202. PubMed ID: 28275299
[TBL] [Abstract][Full Text] [Related]
30. EGFR inhibitor enhances cisplatin sensitivity of oral squamous cell carcinoma cell lines.
Hiraishi Y; Wada T; Nakatani K; Tojyo I; Matsumoto T; Kiga N; Negoro K; Fujita S
Pathol Oncol Res; 2008 Mar; 14(1):39-43. PubMed ID: 18347929
[TBL] [Abstract][Full Text] [Related]
31. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
Xu Y; Jiang Z; Zhang Z; Sun N; Zhang M; Xie J; Li T; Hou Y; Wu D
J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998
[TBL] [Abstract][Full Text] [Related]
32. 14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin αvβ3 and activating FAK/PI3K/AKT signaling.
Luo J; Yao JF; Deng XF; Zheng XD; Jia M; Wang YQ; Huang Y; Zhu JH
J Exp Clin Cancer Res; 2018 Feb; 37(1):23. PubMed ID: 29426357
[TBL] [Abstract][Full Text] [Related]
33. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
34. Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
Su J; Zhang F; Li X; Liu Z
Biochem Biophys Res Commun; 2019 Jun; 514(2):510-517. PubMed ID: 31056260
[TBL] [Abstract][Full Text] [Related]
35. Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells.
Peng DJ; Wang J; Zhou JY; Wu GS
Biochem Biophys Res Commun; 2010 Apr; 394(3):600-5. PubMed ID: 20214883
[TBL] [Abstract][Full Text] [Related]
36. Reversal of cisplatin resistance by inhibiting PI3K/Akt signal pathway in human lung cancer cells.
Zhang Y; Bao C; Mu Q; Chen J; Wang J; Mi Y; Sayari AJ; Chen Y; Guo M
Neoplasma; 2016; 63(3):362-70. PubMed ID: 26925782
[TBL] [Abstract][Full Text] [Related]
37. Rab25 is responsible for phosphoinositide 3-kinase/AKT‑mediated cisplatin resistance in human epithelial ovarian cancer cells.
Fan Y; Wang L; Han X; Liu X; Ma H
Mol Med Rep; 2015 Mar; 11(3):2173-8. PubMed ID: 25405658
[TBL] [Abstract][Full Text] [Related]
38. Antitumor effect of a Pt-loaded nanocomposite based on graphene quantum dots combats hypoxia-induced chemoresistance of oral squamous cell carcinoma.
Wei Z; Yin X; Cai Y; Xu W; Song C; Wang Y; Zhang J; Kang A; Wang Z; Han W
Int J Nanomedicine; 2018; 13():1505-1524. PubMed ID: 29559779
[TBL] [Abstract][Full Text] [Related]
39. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells.
Eckstein N; Servan K; Hildebrandt B; Pölitz A; von Jonquières G; Wolf-Kümmeth S; Napierski I; Hamacher A; Kassack MU; Budczies J; Beier M; Dietel M; Royer-Pokora B; Denkert C; Royer HD
Cancer Res; 2009 Apr; 69(7):2996-3003. PubMed ID: 19318572
[TBL] [Abstract][Full Text] [Related]
40. Moving beyond cisplatin resistance: mechanisms, challenges, and prospects for overcoming recurrence in clinical cancer therapy.
Fu R; Zhao B; Chen M; Fu X; Zhang Q; Cui Y; Hu X; Zhou W
Med Oncol; 2023 Dec; 41(1):9. PubMed ID: 38063931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
